Reata Pharmaceuticals, Inc. Class A

RETA

$111.93

-42.92% (1 year change)

Avg closing price

Price range

Market Cap

$3.54 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$1.4 Million

Total revenue in the last quarter.

Net Income

-$65.5 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

-$11.19

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-9.58x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-54.4 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Reata Pharmaceuticals, Inc. Class A

News

Worldwide Movie Theatres Industry to 2024 - Featuring AMC, Regal Entertainment and Cinemark

Worldwide Movie Theatres Industry to 2024 - Featuring AMC, Regal Entertainment and Cinemark

DUBLIN, Dec. 16, 2020 /PRNewswire/ -- The "Global Movie Theatres Market: Size & Forecasts with Impact Analysis of COVID-19 (2020-2024 Edition)" report has been added to ResearchAndMarkets.com's off...

PR Newswire PR Newswire, about 1 month ago
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the Unite...

Business Wire Business Wire, about 1 month ago
Deadline on Dec. 14th coming up in Lawsuit for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares

Deadline on Dec. 14th coming up in Lawsuit for Investors in Reata Pharmaceuticals, Inc. (NASDAQ: RETA) shares

A deadline is coming up on December 14, 2020 in the lawsuit filed for certain investors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) over alleged securities laws violations by Reata Pharmaceutical...

OpenPR OpenPR, about 1 month ago